Neeltje Steeghs
Overview
Explore the profile of Neeltje Steeghs including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
175
Citations
3779
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Meertens M, Rosing H, Steeghs N, Beijnen J, Huitema A
Biomed Chromatogr
. 2025 Mar;
39(5):e70056.
PMID: 40084678
Home-sampling for therapeutic drug monitoring (TDM) for oral targeted anticancer drugs offers a promising alternative to traditional hospital-based sampling methods, though it presents challenges. This review aims to summarize the...
2.
Mohammadi M, Roets E, Bleckman R, Oosten A, Grunhagen D, Desar I, et al.
Cancers (Basel)
. 2025 Feb;
17(4).
PMID: 40002229
Background: Neoadjuvant imatinib therapy plays a crucial role in the management of gastrointestinal stromal tumors (GISTs), but its impact across various mutational profiles remains uncertain. Objective: The aim of this...
3.
Meertens M, Kerssemakers N, de Vries N, Rosing H, Steeghs N, Beijnen J, et al.
Ther Drug Monit
. 2025 Feb;
PMID: 39996568
Background: Therapeutic Drug Monitoring optimizes oral anticancer drug treatment by measuring plasma levels. Volumetric absorptive microsampling (VAMS) allows home sampling with a minimal blood sample. However, methods for converting whole...
4.
van der Kleij M, Meertens M, Groenland S, Kordes S, Bergman A, de Feijter J, et al.
Br J Cancer
. 2025 Feb;
PMID: 39934337
Background: Previous studies demonstrated better outcomes for mCRPC (metastatic castration resistant prostate cancer) patients with higher abiraterone exposure (minimal plasma concentration (C) > 8.4 ng/mL), but around 40% of patients...
5.
Meertens M, Giraud E, Hassan E, Zielhuis S, Snels T, Desar I, et al.
Cancer Chemother Pharmacol
. 2025 Jan;
95(1):25.
PMID: 39820703
Purpose: After initial approval of lenvatinib for radioiodine-refractory differentiated thyroid cancer (DTC), it has also shown promising outcomes in among others metastatic renal cell carcinoma (mRCC). Given that trial populations...
6.
Van Riet B, Van Meekeren M, Fiocco M, Miah A, De Pree I, Wiltink L, et al.
Acta Oncol
. 2025 Jan;
64():69-77.
PMID: 39813174
Objective: This study aims to assess the long-term safety and efficacy of adding pazopanib to neo-adjuvant radiotherapy followed by surgery in patients with high-risk non-metastatic soft tissue sarcoma of the...
7.
Lopez J, Powles T, Braiteh F, Siu L, LoRusso P, Friedman C, et al.
Nat Med
. 2025 Jan;
31(1):152-164.
PMID: 39762422
Effective targeting of somatic cancer mutations to enhance the efficacy of cancer immunotherapy requires an individualized approach. Autogene cevumeran is a uridine messenger RNA lipoplex-based individualized neoantigen-specific immunotherapy designed from...
8.
Mohmaed Ali M, Nijstad A, Boosman R, Crombag M, Barnett S, Veal G, et al.
Clin Pharmacokinet
. 2024 Nov;
63(12):1711-1722.
PMID: 39549227
Background: The effect of age on doxorubicin pharmacokinetics remains inconclusive, especially in patients at the extremes of the age spectrum. We developed a population pharmacokinetic model to further investigate the...
9.
van der Burg S, Reijers S, Kuijpers A, Heimans L, Scholten A, Haas R, et al.
Breast
. 2024 Oct;
78:103825.
PMID: 39476458
Background: Radiation associated angiosarcoma (RAAS) of the breast is a rare malignancy with poor survival. Optimal treatment strategies remain uncertain due to a lack of data, and vary between surgery...
10.
Hansen A, Gomez-Roca C, Robbrecht D, Verlingue L, Italiano A, Bauman J, et al.
Clin Cancer Res
. 2024 Oct;
30(24):5540-5547.
PMID: 39422604
Purpose: This phase Ib trial evaluated fibroblast activation protein-α-targeted IL2 variant (FAP-IL2v), a novel immunocytokine engineered to minimize CD25-mediated toxicities, in combination with cetuximab, in patients with recurrent, unresectable, or...